Australian Clinical Labs Limited
ACL
Rank in Stocks
#13045
Australian Clinical Labs Limited operates across Australia, delivering a... Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
Share Price
$2.25
Last synced: 2026-11-10
Market Cap
$419.60M
Change (1 day)
-0.91%
Change (1 year)
27.98%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Australian Clinical Labs Limited (ACL)
Category
Healthcare
EPS for Australian Clinical Labs Limited (ACL)
EPS as of June 2026 TTM: $0.08
According to Australian Clinical Labs Limited's latest financial reports, its current EPS (TTM) is $0.08. At the end of 2025 the company had an EPS of $0.11, an increase over its 2024 EPS of $0.08.
EPS history for Australian Clinical Labs Limited from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.08 | -23.00% |
| 2025 | $0.11 | 39.70% |
| 2024 | $0.08 | -33.19% |
| 2023 | $0.12 | -80.47% |
| 2022 | $0.61 | 104.70% |
| 2021 | $0.30 | 117.32% |
| 2020 | $0.14 | -478.08% |
| 2019 | $-0.04 | 10.61% |
| 2018 | $-0.03 | -63.97% |
| 2017 | $-0.09 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $18.99 | 22,320.31% |
US
|
|
| $6.12 | 7,125.50% |
US
|
|
| $1.38 | 1,525.86% |
CN
|
|
| $14.83 | 17,408.85% |
US
|
|
| $5.09 | 5,909.45% |
US
|
Questions about Australian Clinical Labs Limited's earnings per share (EPS)
What is Australian Clinical Labs Limited's earnings per share (EPS)?
Australian Clinical Labs Limited's earnings per share (EPS) over the last twelve months is $0.08, as of Jun 2026.
What was Australian Clinical Labs Limited's earnings per share (EPS) in 2025?
In 2025, Australian Clinical Labs Limited's earnings per share (EPS) was $0.11, 37.50% more than in 2024 ($0.08).
How has Australian Clinical Labs Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Australian Clinical Labs Limited's earnings per share (EPS) went from $0.14 to $0.11, an average decline of 4.71% a year.
How does Australian Clinical Labs Limited's earnings per share (EPS) compare with similar companies?
Australian Clinical Labs Limited's earnings per share (EPS) ($0.08) is lower than that of all 5 similar companies listed above. The highest among them is Thermo Fisher Scientific Inc., with $18.99.